Obeticholic Acid
Hepatic Decompensation and Failure in Incorrectly Dosed PBC Patients with Child-Puch Class B or C or Decompensated Cirrhosis
- In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with primary biliary cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when OCALIVA was dosed more frequently than recommended
- The recommended starting dosage of OCALIVA is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior decompensation event
FDA and Industry Communications
Patient Counseling Information
Medication Guides
Package Inserts
Updated March 2018